지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.10
- 수록면
- 985 - 995 (11page)
- DOI
- 10.4143/crt.2021.857
이용수
초록· 키워드
오류제보하기
Purpose This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF) or bronchial washing fluid (BWF), and pleural effusion.
Materials and Methods Among patients benefited from previous EGFR–tyrosine kinase inhibitor (TKI) treatment followed by treatment failure, patients in whom T790M mutations are detected in at least one of the samples including tumor tissues, BALF/BWF, plasma, and pleural effusion were enrolled. T790M mutation was detected by extracting cell free DNA from liquid biopsy samples, using PANA Mutyper. Objective response rate (ORR) and progression-free survival (PFS) with osimertinib treatment were evaluated.
Results Between January 2018 and December 2019, 63 patients were enrolled and received osimertinib. Mean age was 63 years, and 38 (60.3%) were female. Twenty-six patients had T790M mutation in both liquid and tissue samples (group A), 19 patients had only in tissue biopsy samples (group B), and 18 patients had T790M mutation only in liquid biopsy samples (group C). ORR in overall population was 63.5%, and was 61.5% in group A, 68.4% in group B, and 61.1% in group C, respectively. Median PFS in overall patients was 15.6 months (95% confidence interval, 10.7 to 24.2). There was no significant difference in ORR or PFS between groups.
Conclusion Osimertinib showed favorable efficacy in lung cancer patients with acquired resistance to prior EGFR-TKI therapies, who screened positive for harboring T790M mutation detected from cell free DNA extracted from plasma, BALF/BWF, and pleural effusion.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Liquid biopsy: Where did it come from, what is it, and where is it going?
Investigative and Clinical Urology
2019 .01
-
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Cancer Research and Treatment
2020 .01
-
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment
2021 .01
-
Liquid biopsy using extracellular vesicle?derived DNA in lung adenocarcinoma
Journal of Pathology and Translational Medicine
2020 .01
-
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cancer Research and Treatment
2019 .01
-
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
Yonsei Medical Journal
2019 .01
-
Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Journal of Pathology and Translational Medicine
2020 .01
-
Importance of the Cell Block Technique in Diagnosing Patients with Non-Small Cell Carcinoma Accompanied by Pleural Effusion
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer
Journal of Gastric Cancer
2024 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
Investigative and Clinical Urology
2021 .01
-
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Cancer Research and Treatment
2019 .01
-
Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma
Journal of Liver Cancer
2022 .09
-
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Cancer Research and Treatment
2019 .01
-
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
Cancer Research and Treatment
2018 .01
-
Comparative Assessment of the Diagnostic Value of Transbronchial Lung Biopsy and Bronchoalveolar Lavage Fluid Cytology in Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Journal of Pathology and Translational Medicine
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0